X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
life sciences & biomedicine (8) 8
science & technology (8) 8
bay 94-8862 (7) 7
heart failure (7) 7
heart failure - drug therapy (6) 6
finerenone (5) 5
aged (3) 3
animals (3) 3
antagonist (3) 3
cardiac & cardiovascular systems (3) 3
cardiovascular system & cardiology (3) 3
double-blind (3) 3
double-blind method (3) 3
mineralocorticoid receptor antagonists - adverse effects (3) 3
mineralocorticoid receptor antagonists - pharmacology (3) 3
mineralocorticoid receptor antagonists - therapeutic use (3) 3
naphthyridines - adverse effects (3) 3
naphthyridines - pharmacology (3) 3
naphthyridines - therapeutic use (3) 3
task-force (3) 3
bay 94‐8862 (2) 2
brain natriuretic peptide (2) 2
care and treatment (2) 2
chronic disease (2) 2
chronic kidney disease (2) 2
diabetic nephropathies - drug therapy (2) 2
diabetic nephropathy (2) 2
efficacy (2) 2
female (2) 2
heart (2) 2
heart failure - metabolism (2) 2
left-ventricular dysfunction (2) 2
male (2) 2
middle aged (2) 2
mineralocorticoid receptor (2) 2
mineralocorticoid receptor antagonist (2) 2
mineralocorticoid receptor antagonists (2) 2
natriuretic peptide, brain (2) 2
peptide fragments (2) 2
pharmacology & pharmacy (2) 2
renal insufficiency, chronic (2) 2
renal insufficiency, chronic - drug therapy (2) 2
spironolactone (2) 2
spironolactone - analogs & derivatives (2) 2
treatment outcome (2) 2
trial (2) 2
type 2 diabetes mellitus (2) 2
3400 (1) 1
[sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
abridged index medicus (1) 1
acute myocardial-infarction (1) 1
adult (1) 1
albumin (1) 1
albuminuria - drug therapy (1) 1
albuminuria - urine (1) 1
aldosterone (1) 1
aldosterone antagonists (1) 1
aldosterone breakthrough (1) 1
angiotensin receptor antagonists - therapeutic use (1) 1
angiotensin-aldosterone system (1) 1
angiotensin-converting enzyme inhibitors - therapeutic use (1) 1
antihypertensive agents - therapeutic use (1) 1
area under curve (1) 1
arts (1) 1
bardoxolone methyl (1) 1
bay 94–8862 (1) 1
binding sites (1) 1
biomedicine (1) 1
biotransformation (1) 1
blood pressure (1) 1
cardiac patients (1) 1
cardiology and cardiovascular system (1) 1
cardiorenal disease (1) 1
cardiorenal end-points (1) 1
cardiovascular agents (1) 1
cardiovascular agents - pharmacology (1) 1
cardiovascular agents - therapeutic use (1) 1
chronic heart-failure (1) 1
chronic kidney failure (1) 1
chronic kidney-disease (1) 1
clinical trials as topic (1) 1
clinical trials, phase ii as topic (1) 1
clinical trials, phase iii as topic (1) 1
comorbidity (1) 1
computer simulation (1) 1
converting enzyme-inhibitor (1) 1
creatinine - urine (1) 1
diabetes mellitus (1) 1
diabetes mellitus, type 2 (1) 1
diabetes mellitus, type 2 - blood (1) 1
diabetes mellitus, type 2 - complications (1) 1
diabetes mellitus, type 2 - drug therapy (1) 1
diabetic kidney disease (1) 1
diabetic nephropathies (1) 1
diabetic nephropathies - etiology (1) 1
diabetic nephropathies - metabolism (1) 1
diabetic nephropathies - physiopathology (1) 1
diabetic nephropathies - urine (1) 1
diabetic retinopathy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
European journal of heart failure, ISSN 1388-9842, 02/2015, Volume 17, Issue 2, pp. 224 - 232
AimsTo investigate the safety and potential efficacy of the novel non-steroidal mineralocorticoid receptor antagonist finerenone in patients with worsening... 
Heart failure | BRAIN NATRIURETIC PEPTIDE | ALDOSTERONE ANTAGONISTS | FOLLOW-UP | Chronic kidney disease | Type 2 diabetes mellitus | HOSPITAL DISCHARGE | TRIAL | TASK-FORCE | Mineralocorticoid receptor | SPIRONOLACTONE | EUROBSERVATIONAL RESEARCH-PROGRAM | BAY 94-8862 | DOUBLE-BLIND | Antagonist | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Double-Blind Method | Comorbidity | Naphthyridines - adverse effects | Humans | Natriuretic Agents - blood | Mineralocorticoid Receptor Antagonists - adverse effects | Heart Failure - blood | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - blood | Diabetes Mellitus, Type 2 - blood | Naphthyridines - therapeutic use | Peptide Fragments - blood | Spironolactone - analogs & derivatives | Diabetes Mellitus, Type 2 - drug therapy | Spironolactone - therapeutic use | Natriuretic Peptide, Brain - blood | Spironolactone - adverse effects | Index Medicus | Renal Insufficiency, Chronic | Peptide Fragments | Naphthyridines | Life Sciences | Human health and pathology | Spironolactone | Natriuretic Peptide, Brain | Heart Failure | Natriuretic Agents | Diabetes Mellitus, Type 2 | Mineralocorticoid Receptor Antagonists | Cardiology and cardiovascular system
Journal Article
Journal Article
American journal of nephrology, ISSN 1421-9670, 2014, Volume 40, Issue 6, pp. 572 - 581
Background/Aims: Finerenone decreases albuminuria in patients having heart failure with reduced ejection fraction and mild-to-moderate (stage 2-3) chronic... 
Original Report: Patient-Oriented, Translational Research | Heart failure | CHRONIC HEART-FAILURE | RENAL-DISEASE | Type 2 diabetes mellitus | CARDIORENAL END-POINTS | II RECEPTOR BLOCKERS | TASK-FORCE | Mineralocorticoid receptor | BARDOXOLONE METHYL | BAY 94-8862 | ALDOSTERONE BREAKTHROUGH | Diabetic nephropathy | Antagonist | CHRONIC KIDNEY-DISEASE | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Blood Pressure | Diabetic Nephropathies - etiology | Naphthyridines - adverse effects | Humans | Middle Aged | Familial Primary Pulmonary Hypertension - drug therapy | Diabetic Nephropathies - drug therapy | Male | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Female | Albuminuria - urine | Diabetes Mellitus, Type 2 - complications | Diabetic Nephropathies - urine | Mineralocorticoid Receptor Antagonists - administration & dosage | Glomerular Filtration Rate | Double-Blind Method | Mineralocorticoid Receptor Antagonists - adverse effects | Antihypertensive Agents - therapeutic use | Creatinine - urine | Albuminuria - drug therapy | Potassium - blood | Aged | Familial Primary Pulmonary Hypertension - complications | Angiotensin Receptor Antagonists - therapeutic use | Naphthyridines - administration & dosage | Heart | Type 2 diabetes | Diabetic retinopathy | Care and treatment | Chronic kidney failure | Diabetic nephropathies | Albumin | Research | Diagnosis | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.